Reactive oxygen species and erectile dysfunction: Possible role of NADPH oxidase

International Journal of Impotence Research

Volumn 19, Issue 3, 2007, Pages 265-280

  Jeremy, J Y ^a   Jones, R A ^a   Koupparis, A J ^a   Hotston, M ^a   Persad, R ^a   Angelini, G D ^a   Shukla, N ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Erectile dysfunction; NADPH oxidase; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; APOCYNIN; ASCORBIC ACID; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; FREE RADICAL; ICOSANOID; ILOPROST; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); NITRIC OXIDE; OXIDOREDUCTASE INHIBITOR; PENICILLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLANT EXTRACT; POMEGRANATE EXTRACT; PROBUCOL; PROSTACYCLIN; PROSTAGLANDIN E1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELENATE; SILDENAFIL; SILDENAFIL NITRATE; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VAS 2870; VITAMIN D;

ANTIOXIDANT ACTIVITY; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIET; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOXIA; ISCHEMIA; LIFESTYLE; NONHUMAN; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOLOGY; PENIS ERECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR DISEASE;

ANIMALS; HUMANS; IMPOTENCE; MALE; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 34247897143     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901523     Document Type: Review

References (213)

1. Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-56.
2. Roumeguere T, Wespes E, Carpentier Y, Hoffman P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; 44: 355-359.
3. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S et al. Erectile dysfunction in the cardiac patient: how common and how should we treat it. J Urol 2003; 170: S46-S50.
4. Solomon H, Mann JW, Jackson G. Erectile dysfunction and the cardiovascular patient. Heart 2003; 89: 251-254.
5. Barrett-Connor E. Cardiovascular risk stratification and cardiovascular risk factors associated with erectile dysfunction: assessing cardiovascular risk in men with erectile dysfunction. Clin Cardiol 2004; 274: I8-13.
6. Kostis JB, Jackson G, Rosen R, Barrett-Connor K, Billups A, Burnett C et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313-321.
7. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001; 53: 417-450.
8. Lue TF. Erectile dysfunction. N Engl J Med 2000; 432: 1802-1813.
9. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96: 257-280.
10. Giuliano F, Rampin O. Neural control of erection. Physiol Behav 2004; 83: 189-201.
11. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol 2005; 76: 1-21.
12. Goldstein I, Udelson D. Axial penile rigidity: determinants and relation to hemodynamic parameters. Int J Impot Res 1998; 10: S28-S33.
13. Schwartz AN, Wang KY, Mack LA. Evaluation of normal erectile function with colour flow Doppler sonography. Am J Roentgenol 1989; 153: 1153-1160.
14. Fournier GR, Juenemann KP, Lue TF, Tanagho EA. Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration. J Urol 1987; 137: 163-167.
15. Aboseif SR, Lue TF. Haemodynamics of penile erection. Urol Clin N Amer 1988; 15: 1-7.
16. Shirai M, Ishii N. Haemodynamics of erection in man. Arch Androl 1981; 6: 27-32.
17. Vardi Y, Siroky MB. Hemodynamics of pelvic nerve induced erection in a canine model. I. Pressure and flow. J Urol 1990; 144: 794-797.
18. Saenz-de Tejada IS, Moroukian P, Tessier J, Kim JJ, Goldstein I, Frohrib D. Trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model. Am J Physiol 1991; 260: H1590-H1595.
19. Goldstein I, Udelson D. Axial penile rigidity: determinants and relation to hemodynamic parameters. Int J Impot Res 1998; 10: S28-S33.
20. Schwartz AN, Wang KY, Mack LA. Evaluation of normal erectile function with colour flow Doppler sonography. Am J Roentgenol 1989; 153: 1153-1160.
21. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843-850.
22. Rajfer J, Aronson WJ, Bush PA, eDorey F, Ignarro I. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-94.
23. Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erection. Pharmacol Ther 2005; 106: 233-266.
24. Nangle MR, Cotter MA, Cameron NE. An in vitro investigation of aorta and corpus cavernosum from eNOS and iNOS gene deficient mice. Pflugers Arch Eur J Physiol 2004; 448: 139-145.
25. Bivalacqua TJ, Champion HC, Mehta YS, Abdel-Mageed AC, Sikka SC, Ignarro LJ et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res 2000; 12(Suppl 3): S8-S17.
26. Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 2004; 16: S15-S19.
27. Musicki B, Burnett AL. Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res 2006 (E-pub: in press).
28. Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 2004; 16 (Suppl 1): S15-S19.
29. Hurt KJ, Sezen SF, Champion HC, Crone JK, Palese MA, Huanget PL et al. Alternatively spliced neuronal nitric oxide synthase mediates penile erection. PNAS 2006; 103: 3440-3443.
30. Nangle MR, Cotter MA, Cameron NE. An in vitro investigation of aorta and corpus cavernosum from eNOS and nNOS gene-deficient mice. Pflugers Arch 2004; 448: 139-145.
31. Hofmann F. The biology of cyclic GMP dependent protein kinases. J Biol Chem 2005; 280: 1-4.
32. Jeremy JY, Yim AP, Wan S, Angelini GD. Oxidative stress, nitric oxide and vascular disease. J Cardiovasc Surg 2002; 17: 324-327.
33. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and vascular smooth muscle cell proliferation. Cardiovasc Res 1999; 43: 658-665.
34. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. NADPH oxidases: a promiscuous target for cardiovascular drugs? Trends Cardiovasc Med 2005; 15: 278-282.
35. Jeremy JY, Ballard SA, Naylor AM, Miler MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum, in vitro. Br J Urol Int 1997; 79: 958-963.
36. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164-2171.
37. Corbin J, Rannels S, Neal D, Chang P, Grimes K, Beasley A et al. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin 2003; 19: 747-752.
38. Palumbo F, Bettocchi C, Selvaggi FP, Pryor JP, Ralph DJ. Sildenafil: efficacy and safety in daily clinical practice. Eur Urol 2001; 40: 176-180.
39. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92: 9M-18M.
40. Cashen DE, MacIntyyre DE, Martin WJ. Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase. Br J Pharmacol 2002; 136: 693-700.
41. Shukla N, Jones RAW, Persad R, Jeremy JY. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 2005; 517: 224-231.
42. phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 2005; 146: 109-117.
43. 2 mimetic, U46619, in corpus cavernosal smooth muscle cells. Br J Urol Int 2005; 96: 423-427.
44. Malmstrom BG. Enzymology of oxygen. Ann Rev Biochem 1982; 51: 21-59.
45. Betteridge DJ. What is oxidative stress? Metabolism 2000; 49: 3-8.
46. Shah AM, Channon KM. Free radicals and redox signalling in cardiovascular disease. Heart 2004; 90: 486-487.
47. Kojda G, Harrison D. Interaction between NO and reactive oxygen species: pathological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-571.
48. Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000; 28: 1456-1462.
49. Bergendi L, Bens L, Durackova Z, Ferencik M. Chemistry, physiology and pathology of free radicals. Life Sci 1999; 65: 1865-1874.
50. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 2000; 28: 1780-1794.
51. Jeremy JY, Angelini GD, Khan M, Mikhailidis DP, Morgan RJ, Thompson CS et al. Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc Res 2000; 46: 50-54.
52. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 2000; 87: 840-844.
53. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-478.
54. Jeremy JY, Shukla N, Muzaffar S, Angelini GD. Reactive oxygen species, vascular disease and cardiovascular surgery. Curr Vasc Pharmacol 2004; 2: 229-236.
55. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good the bad and the ugly. Am J Physiol 1996; 271: C1424-C1437.
56. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 2001; 54: 176-186.
57. Dweik RA. Nitric oxide, hypoxia, and superoxide: the good, the bad, and the ugly!. Thorax 2005; 60: 265-267.
58. Folkerts G, Kloek J, Muijsers RB, Nijkamp FP. Reactive nitrogen and oxygen species in airway inflammation. Eur J Pharmacol 2001; 429: 251-262.
59. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol 2004; 287: R1014-R1030.
60. Martin W, McAllister KHM, Paisley K. NANC neurotransmission in the bovine retractor penis muscle is blocked by superoxide anion following inhibition of superoxide dismutase with diethyldthiocarbamate. Neuropharmacology 1994; 33: 1293-1301.
61. Gillespie JS, Sheng H. The effects of pyrogallol and hydroquinone on the response to NANC nerve stimulation in the rat anococcygeus and the bovine retractor penis muscles. Br J Pharmacol 1990; 99: 194-196.
62. Bivalacqua TT, Armstrong JS, Biggerstaff J, Abdel Mageed AB, Kadowotz PJ, Hellstrom WJ et al. Gene transfer of SOD to the penis reduces superoxide formation and improves erectile function in aged rats. Am J Physiol 2003; 284: H1408-H1421.
63. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000; 20: 2175-2183.
64. Landmesser U, Harrison DG, Drexler H. Oxidant stress - a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 2006; 62(Suppl 13): 13-19.
65. Mungrue IN, Bredt DS, Stewart DJ, Husain M. From molecules to mammals: what's NOS got to do with it? Acta Physiol Scand 2003; 179: 123-135.
66. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
67. Li H, Poulos TL. Structure-function studies on nitric oxide synthases. J Inorg Biochem 2005; 99: 293-305.
68. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol 2001; 280: F193-F206.
69. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, Jo H. Coordinated regulation of endothelial nitric oxide activity by phoapshorylation and subcellular localization. Free Rad Biol Med 2006; 41: 144-153.
70. 2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 2001; 88: 68-75.
71. Church JE, Fulton D. Differences in eNOS activity because of subcellular localization are dictated by phosphorylation state rather than the local calcium environment. J Biol Chem 2006; 281: 1477-1488.
72. Jagnandan D, Sessa WC, Fulton D. Intracellular location regulates calcium-calmodulin-dependent activation of organelle-restricted eNOS. Am J Cell Physiol 2005; 289: C1024-C1033.
73. Chiarugi P. PTPs versus PTKs: the redox side of the coin. Free Rad Res 2005; 39: 353-364.
74. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-242.
75. Butt E, Bernhardt M, Smolenski A. Endothelial nitric-oxide synthase (Type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J Biol Chem 2000; 275: 5179-5187.
76. Michell BJ, Chen ZP, Tiganis T, Stapleton D, Katsis F, Power DA et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001; 276: 17625-17628.
77. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 400: 597-601.
78. Fulton D, Church JE, Ruan L, Sood G, Kemp BE, Jennings IG et al. Src kinase activates endothelial nitric-oxide synthase by phosphorylating Tyr-83. J Biol Chem 2005; 280: 3594-35952.
79. Peterson TE, Poppa V, Ueba H, Wu A, Yan C, Berk BC. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res 1999; 85: 29-37.
80. Jin L, Ying Z, Webb RC. Activation of the Rho/Rho kinase pathway by reactive oxygen species in the rat aorta. Am J Physiol 2006; 287: H1495-H1500.
81. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-24271.
82. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
83. Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis regeneration and functions. Biochem J 2000; 347: 1-16.
84. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial nitric oxide synthase in hypertension: role of the NAD(P)H oxidase. J Clin Invest 2003; 111: 1201-1209.
85. Gloire G, Legrand-Poels S, Piette J. NFkappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006 (E-pub; in press).
86. Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol 1998; 275: C1640-C1652.
87. Carballo M, Conde M, El Bekay R, Martín-Nieto J, Camacho MJ, Monteseirín J et al. Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes. J Biol Chem 1999; 274: 17580-17586.
88. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
89. Cuzzocrea S. Shock, inflammation and PARP. Pharmacol Res 2005; 52: 72-82.
90. Hayashi T, Juliet PA, Kano-Hayashi H, Tsunekawa T, Dingqunfang D, Sumi D et al. NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and -independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction. Diab Obes Metab 2005; 7: 334-343.
91. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci 2003; 73: 1813-1824.
92. Shukla N, Koupparis A, Persad R, Angelini GD, Jeremy JY. Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation and superoxide formation in the aorta of the rabbit. Eur J Pharmacol 2006; 531: 201-208.
93. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003; 107: 1053-1058.
94. Jacobson GM, Dourron HM, Liu J, Carretero OA, Reddy DJ, Andrzejewskiet T et al. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res 2003; 92: 637-643.
95. phox and endothelial nitric oxide synthase in the pulmonary artery. Thorax 2005; 60: 305-313.
96. Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res 2004; 94: 37-45.
97. Zhang H, Schmeiber A, Garlichs CD, Plötze K, Damme U, Mügge A et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999; 44: 215-222.
98. 2α and cytokines. Br J Pharmacol 2004; 141: 488-496.
99. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ET(B) receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 2005; 145: 323-333.
100. McNally JS, Davis ME, Giddens DP, Saha A. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol 2003; 285: H2290-H2297.
101. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Superoxide auto-augments superoxide formation and upregulates gp91(phox) expression in porcine pulmonary artery endothelial cells: Inhibition by iloprost. Eur J Pharmacol 2006; 538: 108-114.
102. Muzaffar S, Jeremy JY, Angelini GD, Shukla N. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 2003; 58: 598-604.
103. phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells. Circulation 2004; 110: 1140-1147.
104. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Prednisolone augments superoxide formation in porcine pulmonary artery endothelial cells through upregulation of NADPH oxidase. Br J Pharmacol 2005; 145: 688-697.
105. Michal V. Arterial disease as a cause of impotence. Clinics Endocrinol Metab 1982; 11: 725-748.
106. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1(8422): 181-184.
107. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
108. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen J, Skatchkov M et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis. Circulation 1999; 99: 2027-2033.
109. Guzik TZ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-E90.
110. Kim SC. Hyperlipidemia and erectile dysfunction. Asian J Androl 2000; 2: 161-166.
111. Azadzoi KM, Goldstein I. Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model. J Urol 1992; 147: 1675-1681.
112. Kim JH, Klyachkin ML, Svendsen E, Davies MG, Hagen PO, Carson III CC. Experimental hypercholesterolaemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. J Urol 1994; 151: 198-205.
113. Kim SC, Kim IK, Seo KK, Baek KJ, Lee MY. Involvement of superoxide radical in the impaired endothelium-dependant relaxation of cavernous smooth muscle in hypercholesterolaemic rabbits. Urol Res 1997; 25: 341-346.
114. Grein U, Schubert GE. Arteriosclerosis of penile arteries. Urol Int 2002; 68: 261-264.
115. Seo KK, Yun HY, Kim SC. Involvement of endothelial NOS in the impaired endothelium dependent relaxation of cavernosal smooth muscle in hypercholesterolaemic rabbits. J Androl 1999; 20: 298-306.
116. Mugge A, Brandes RP, Boger RH, Dwenger A, Bode Boger S, Kienke S et al. Vascular release of superoxide radicals is enhanced in hypercholesterolaemic rabbits. J Cardiovasc Pharmacol 1994; 24: 994-998.
117. Rizvi K, Hapson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 567: 95-98.
118. Nangle MR, Cotter MA, Cameron NE. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 2003; 52: 2396-2402.
119. Osborne T. Statin treatment improves erectile dysfunction in sildenafil nonresponders. Nat Clin Pract Urol 2006; 3: 239-240.
120. Solomon H, Samarasinghe YP, Feher MD, Man J, Rivas-Toro H, Lumb PJ et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60: 141-145.
121. Endres M, Laufs U. Effects of statins on endothelium and signalling mechanisms. Stroke 2004; 35: 2708-2711.
122. Gazzaruso C. Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. Expert Rev Cardiovasc Ther 2006; 4: 173-1780.
123. Kloner RA. Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient. Endocrine 2004; 23: 125-129.
124. De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F et al. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia 2001; 44: 1155-1160.
125. Zheng H, Fan W, Li G, Tam T. Predictors for erectile dysfunction among diabetics. Diab Res Clin Pract 2005; 71: 313-319.
126. Cameron NE, Eaton SEM, Cotter MA, Tesfayre S. Vascular factors and metabolic interactions in the pathogenesis of diabetic angiopathy. Diabetologia 2001; 44: 1973-1988.
127. Burnett AL. Metabolic syndrome, endothelial dysfunction, and erectile dysfunction: association and management. Curr Urol Rep 2005; 6: 470-475.
128. Saenz de Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. New Eng J Med 1989; 320: 1025-1030.
129. Cartledge JJ, Eardley I, Morrison JFB. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 2001; 87: 394-401.
130. Azadzoi K, Tejada ISD. Diabetes mellitus impairs neurogenic and endothelium dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1992; 148: 1587-1591.
131. Yildrim S, Ayan S, Sarioglu Y, Gültekin Y, Bütüner C. The effects of long-term oral administration of L-arginine on the erectile response of rabbits with alloxan-induced diabetes. BJU Int 1999; 83: 679-685.
132. Gur S, Ozturk B, Karahan ST. Impaired endothelium-dependent and neurogenic relaxation of corpus cavernosum from diabetic rats: improvement with L-arginine. Urol Res 2000; 28: 14-19.
133. Thompson C, Mumtaz FH, Khan M, Mikhalidis DP, Wallis RW, Morgna RJ et al. The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. Eur J Pharmacol 2001; 425: 57-64.
134. West IC. Radicals and oxidative stress in diabetes. Diab Med 2000; 17: 171-180.
135. Hayden MR, Tyagi SC. Neural redox stress and remodelling in metabolic syndrome, type 2 diabetes and diabetic neuropathy. Med Sci Monit 2004; 10: RA291-RA307.
136. Khan M, Thompson CS, Jeremy JY, Mumtaz FH, Mikhailidis DP, Morgan RJ. The effect of superoxide dismutase on nitric oxide-mediated and electrical field stimulated diabetic rabbit cavernosal smooth muscle relaxation. BJU Int 2000; 87: 98-103.
137. Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Imp Res 2004; 16: 21-29.
138. Vincent AM, McLean LL, Backus C, Feldman EL. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 2005; 19: 638-640.
139. Didion SP, Faraci FM. Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arterioles. Stroke 2003; 34: 2038-2042.
140. Coppey LJ, Gellett JS, Davidson EP, Yorek MA. Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 2003; 37: 33-40.
141. Coppey LJ, Gellett JS, Davidson EP, Yorek MA. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 2001; 134: 21-29.
142. Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Slowing of motor nerve conduction velocity is streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res 2000; 1: 131-143.
143. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991; 261: E1-E8.
144. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-1937.
145. Galili O, Sattler KJ, Herrmann J, Woodrum J, Olson M, Lerman L et al. Experimental hypercholesterolemia differentially affects adventitial vasa vasorum and vessel structure of the left internal thoracic and coronary arteries. J Thorac Cardiovasc Surg 2005; 129: 762-772.
146. Barker SG, Talbert A, Cottam S, Baskerville PA, Martin JE. Arterial initimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thromb 1993; 13: 70-77.
147. McCully KS. Homocysteine and vascular disease. Nature Med 1996; 2: 386-389.
148. Moat SJ, Doshi SN, Lang D, McDowell IWF, Lewis MJ, Goodfellow J. Treatment of coronary heart disease with folic acid: is there a future? Am J Physiol 2004; 287: H1-H7.
149. Jones RWA, Jeremy JY, Koupparis A, Persad R, Shukla N. Cavernosal dysfunction in a rabbit model of hyperhomocysteinaemia. Br J Urol Int 2005; 95: 125-130.
150. Kouparris A, Jeremy JY, Angelini GD, Persad R, Shukla N. The administration of penicillamine reverses the inhibitory effect of hyperhomocysteinaemia on carbachol-stimulated relaxation of the rabbit cavernosum. Br J Urol 2006; 98: 440-444.
151. Loscalzo J. The oxidant stress of hyperhomocysteinaemia. J Clin Invest 1996; 98: 5-7.
152. Emsley A, Jeremy JY, Gomes G, Angelini GD, Plane F. Copper interacts with homocysteine to inhibit nitric oxide formation in the rat isolated aorta. Br J Pharmacol 1999; 126: 1034-1040.
153. Khan M, Thompson CS, Emsley A, Mumtaz F, Mikhailidis D, Angelini G et al. Homocysteine and copper interact to markedly inhibit the relaxation of the rabbit corpus cavernosum. New risk factors for angiopathic erectile dysfunction? Br J Urol 1999; 84: 720-724.
154. Shukla N, Thompson C, Angelini GD, Mikhailidis DP, Jeremy JY. Low concentrations of copper augment the impairment of endothelium-dependent relaxation of aortae from diabetic rabbits. Metabolism 2004; 53: 1315-1321.
155. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006; 187: 238-250.
156. Shukla N, Angelini GD, Jeremy JY. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 2003; 46: 766-772.
157. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnema T. Elevated plasma homocysteine levels is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Am J Coll Phys 2004; 140: 94-100.
158. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65: 773-786.
159. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiolgy of erection. J Androl 2006; 27: 335-347.
160. Cifuentes ME, Pagano PJ. Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 179-186.
161. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens 2002; 4: 424-432.
162. Fogari R, Zoppi I. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 203; 4: 202-210.
163. Van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005; 2: 856-864.
164. Parikh P, McDaniel MC, Ashen MD, Joseph I, Miller JI, Sorrentino M et al. Diets and cardiovascular disease. J Am Coll Cardiol 2005; 45: 1379-1387.
165. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Kevin Billups K, Burnett AL et al. Sexual dysfunction and cardiac risk (The Second Princeton Concensus Conference). Am J Cardiol 2005; 96: 313-321.
166. Cocores JA, Miller NS, Pottash AC, Gold MS. Sexual dysfunction in abusers of cocaine and alcohol. Am J Drug Alcohol Abuse 1988; 14: 169-173.
167. Rosen M, Greenfield A, Walker T. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 1991; 145: 759-763.
168. Shabsigh R, Fishman IJ, Schum C, Dunn JK. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology 1991; 38: 227-231.
169. Jeremy JY, Mikhailidis DP. Smoking and erectile dysfunction. J Roy Soc Health 1998; 118: 151-155.
170. Koupparis A, Jeremy JY, Persad R, Angelini GD, Shukla N. Smoking and erectile dysfunction: the role of NADPH oxidase. Br J Urol Int 2004; 94: 257-258.
171. Azadzoi KM, Goldstein I, Siroky MB, Traish AM, Krane RJ, Saenz de Tejada I. Mechanism of ischemia induced cavernosal smooth muscle cell relaxation in a rabbit model of vasculogenic erectile dysfunction. J Urol 1998; 160: 2216-2222.
172. Azadzoi KM, Krane RJ, Sanz de Tajeda I, Goldstein I, Siroky MB. Relative roles of cyclooxygenase and nitric oxide synthase pathways in ischemia induced increased contraction of cavernosal smooth muscle. J Urol 1999; 161: 1324-1328.
173. Azadzoi KM, Master TA, Siroky MB. Effect of chronic ischemia on constitutive and inducible nitric oxide synthase expression in erectile tissue. J Androl 2004; 25: 282-388.
174. Kim N, Vardi Y, Padma-Nathan H, Goldstein I, Saenz de Tejada I. Oxygen tension regulates the nitric oxide pathway: physiological role in penile erection. J Clin Invest 1993; 91: 437-442.
175. Moreland R. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res 1998; 10: 113-120.
176. Knipsel H, Andresen R. Evaluation of vasculogenic impotence by monitoring of cavernous oxygen tension. J Urol 1993; 149: 1276-1282.
177. Ikeda E. Cellular responses to tissue hypoxia and its involvement in disease progression. Pathol Int 2005; 55: 603-610.
178. Bertuglia S, Giusti A. Microvascular oxygenation, oxidative stress, NO suppression and superoxide dismutase during postischemic reperfusion. Am J Physiol Heart Circ Physiol 2003; 285: H1064-H1071.
179. Bremer YA, Salloum F, Ockaili R, Chou E, Moskowiotz WB, Kukreja RC. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res 2005; 57: 22-27.
180. Semple PD, Beastall GH, Brown TM, Semple GC. Sex hormone suppression and sexual impotence in hypoxic pulmonary fibrosis. Sexual dysfunction and erectile impotence in chronic obstructive pulmonary disease. Thorax 1984; 39: 46-51.
181. Aasebo U, Gyltnes A, Bremnes RM, Aakvaag A, Slordal L. Reversal of sexual impotence in male patients with chronic obstructive pulmonary disease and hypoxaemia with long term oxygen therapy. J Steroid Biochem Med Biol 1993; 46: 799-803.
182. Jeremy JY, Mikhailidis DP. Prostaglandins and the penis: possible role in impotence. Sex Marital Ther 1990; 5: 155-165.
183. Jeremy JY, Mikhailidis DP. Prostanoids and impotence: aetiological and therapeutic implications. Br J Sex Med 1989; 16: 411-415.
184. Jeremy JY, Mikhailidis DP. Prostaglandins and the aetiology and treatment of erectile dysfunction. In: Ledda A (ed). Vascular Andrology. Springer Verlag: Berlin, 1996, pp 19-28.
185. Urciuoli R, Cantisani TA, Carlini IM, Giuglietti M, Botti FM. Prostaglandin E1 for treatment of erectile dysfunction. Cochraen Dataabase Syst Rev 2004; (2): CD001784.
186. Jeremy JY, Mehta D, Bryan AJ, Lewis D, Angelini GD. Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc Res 2000; 46: 50-54.
187. Jeremy JY, Mikhailidis DP, Thompson CS, Dandona P. Experimental diabetes mellitus inhibits prostacyclin synthesis by the rat penis: pathological implications. Diabetologia 1985; 28: 365-368.
188. Jeremy JY, Mikhailidis DP, Thompson CS, Dandona P. The effect of cigarette smoke and diabetes mellitus on muscarinic stimulation of prostacyclin synthesis by the rat penis. Diab Res 1986; 3: 467-469.
189. Jeremy JY, Thompson CS, Barradas MA, Dandona P. Duration and not severity determines effects on prostacyclin synthesis in the rat aorta, penis and bladder. Prog Lipid Res 1986; 25: 505-507.
190. Jeremy JY, Morgan RJ, Mikhailidis DP, Dandona P. Prostacyclin synthesis by the corpora cavernosa of the human penis: evidence for muscarinic control. Prostagl Leuk Med 1986; 23: 211-216.
191. Jeremy JY, Mikhailidis DP, Dandona P. Muscarinic stimulation of prostacyclin synthesis by the rat penis. Eur J Pharmacol 1986; 123: 67-71.
192. Fink AN, Frishman WH, Azizad M, Agarwal Y. Use of prostacyclin and its analogues in the treatment of cardiovascular disease. Heart Dis 1999; 1: 29-40.
193. Ueno Y, Koike H, Nakamura Y, Ochi Y, Annoh S, Nishio S. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats. Jpn J Pharmacol 1996; 70: 177-182.
194. 2 dual blocker KDI-792. Prostagl Leukot Essent Fatty Acids 1995; 53: 139-145.
195. 2 inhibition. Prostagl Leukot Essent Fatty Acids 1996; 55: 159-165.
196. Morrow JD, Roberts LJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002; 166: S25-S30.
197. Hayden MR, Tyagi SC. Neural redox stress and remodelling in metabolic syndrome, type 2 diabetes and diabetic neuropathy. Med Sci Monit 2004; 10: RA291-RA307.
198. Vincent AM, McLean LL, Backus C, Feldman EL. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 2005; 19: 638-640.
199. Mander P, Brown GC. Activation of microglial NADPH oxidase is synergistic with glial iNOS : a dual key mechanism of inflammatory neurodgeneration. J Neuroinflamm 2005; 2: 2-20.
200. Dai X, Cao X, Kreulen DL. Superoxide anion is elevated in sympathetic neurons in DOCA salt hypertension via activation of NADPH oxidase. Am J Physiol 2006; 290: H1019-H1026.
201. Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991; 261: E1-E8.
202. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-1937.
203. Low PA, Nickander KK. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991; 40: 873-877.
204. Gocmen C, Secilmis A, Kumcu EK, Ertu PU, nder S, Dikmen A et al. Effects of vitamin E and sodium selenate on neurogenic and endothelial relaxation of corpus cavernosum in the diabetic mouse. Eur J Pharmacol 2000; 398: 93-98.
205. Keegan A, Cotter MA, Cameron NE. Effects of diabetes and treatment with the antioxidant alpha-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia 1999; 42: 343-350.
206. Keegan A, Cotter MA, Cameron NE. Corpus cavernosum dysfunction in diabetic rats: effects of combined alpha-lipoic acid and gamma-linoleic acid treatment. Diabetes Metab Res Rev 2001; 17: 380-386.
207. Keegan A, Cotter MA, Cameron NE. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. Free Rad Biol Med 1999; 27: 536-543.
208. Keaney JF, Xu A, Cunningham D, Jackson J, Frei B, Vita JA et al. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest 1995; 195: 2520-2529.
209. Azadzoi KM, Schulman RN, Aviram M, Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. J Urol 2005; 174: 386-393.
210. Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW et al. Chronic administration of phosphodiesterase inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005; 28: 260-266.
211. De Young L, Yu D, Freeman D, Broack GB. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003; 15: 347-354.
212. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in endothelial and vascular wall. Endothelium 2004; 111: 79-88.
213. Freyhaus HT, Huuntgeburth M, Wingler K, Schnitker J, Baumer A, Vantler M et al. Inhibition of ROS liberation by the novel Nox inhibitor VAS2870 attenuates PDGF dependent migration but not proliferation in vascular smooth muscle cells. Cardiovasc Res 2006; 71: 331-341.